Epigenomics AG: Surveys Show That Patients Believe in Blood Tests for Regular Colorectal Cancer Screening
7/7/2011 9:34:58 AM
BERLIN & SEATTLE--(BUSINESS WIRE)--Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostics company, today announced the results of a survey conducted at europacolon’s first European CRC Patient Conference, The Power of Patient Voice 2011, showing that patients believe tests using blood samples would encourage more people to participate in regular screening for colorectal cancer. Of the participants in the survey, more than 50% had previously heard of the possibility of CRC blood testing and more than 70% thought that using a blood test would encourage more people to participate in regular screening for colorectal cancer. Some of the most often mentioned reasons that survey participants gave for preferring blood tests were ease-of-use and simplicity, not having to handle stool samples as necessary for conventional non-invasive testing, and overall fit with other routine blood tests.